Biomarkers of Alzheimer's disease among Mexican Americans

Journal of Alzheimer's Disease

Volumn 34, Issue 4, 2013, Pages 841-849

  O'Bryant, Sid E ^a,b   Xiao, Guanghua ^c   Edwards, Melissa ^a,d   Devous, Michael ^c   Gupta, Veer Bala ^e,f   Martins, Ralph ^e,f   Zhang, Fan ^b   Barber, Robert ^b  

^a University of North Texas Health Science Center   (United States)

^b University of North   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d UNIVERSITY OF NORTH TEXAS   (United States)

^e EDITH COWAN UNIVERSITY   (Australia)

^f HOLLYWOOD PRIVATE HOSPITAL   (Australia)

Author keywords

Alzheimer's disease; biomarkers; Mexican American; neuropsychology

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALPHA 1 ANTITRYPSIN; ANGIOPOIETIN 2; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CD40 ANTIGEN; EPIDERMAL GROWTH FACTOR; FATTY ACID BINDING PROTEIN; GLUCAGON LIKE PEPTIDE 1; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN M; INSULIN; INTERLEUKIN 18; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MIGRATION INHIBITION FACTOR; MYOGLOBIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; PROTEIN S100B; SOMATOMEDIN; TENASCIN; THYROTROPIN; THYROXINE BINDING GLOBULIN; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1;

AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL DEMENTIA RATING; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE FREQUENCY; HISPANIC; HUMAN; INSULIN BLOOD LEVEL; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOM FOREST; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84876368845     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122074     Document Type: Article

References (70)

1. Alzheimer's, Association (2008) Alzheimer's disease facts and figures. Alzheimers Dement 4, 110-133.
2. Jacobsen LA, Kent M, Lee M, Mather M (2011) America's aging population. Population Bulletin, Vol. 66, http://www.prb.org/pdf11/aging-in-america.pdf
3. NovakK, Riggs JA(2004) Hispanics/Latinos and Alzheimer's disease, Alzheimer's Association, Chicago.
4. US Census Bureau (2005) American Fact Finder, http://www.census.gov/
5. O'Bryant SE, Humphreys JD, Schiffer RB, Sutker PB (2007) Presentation of Mexican Americans to a memory disorder clinic. J Psychopathol Behav Assess 29, 137-140. (Pubitemid 47063453)
6. O'Bryant SE, Johnson L, Balldin V, Edwards M, Barber RC, Williams B, Devous M, Sushing B, Knebl J, Hall J (2012) Characterization of Mexican Americans with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 33(2), 373-379.
7. Haan MN, Mungas DM, Gonzalez HM, Ortiz TA, Acharya A, Jagust WJ (2003) Prevalence of dementia in older latinos: The influence of type 2 diabetes mellitus, stroke and genetic factors. J Am Geriatr Soc 51, 169-177. (Pubitemid 36205844)
8. Sundquist J, Winkleby MA (1999) Cardiovascular risk factors in Mexican American adults: A transcultural analysis of NHANES III, 1988-1994. Am J Public Health 89, 723-730. (Pubitemid 29282737)
9. Fitten LJ, Ortiz F, PontonM(2001) Frequency of Alzheimer's disease and other dementias in a community outreach sample of Hispanics. J Am Geriatr Soc 49, 1301-1308. (Pubitemid 33015206)
10. O'Bryant SE, Hobson V, Hall JR,Waring SC, ChanW, Massman P, Lacritz L, Cullum CM (2009) Diaz-Arrastia R for the Texas Alzheimer's Research Consortium Brain-derived neurotrophic factor levels in Alzheimer's disease. J Alzheimers Dis 17, 337-341.
11. rsquo O, Bryant SE, Hobson VL, Hall JR, Barber RC, Zhang S, Johnson L (2010) Diaz-Arrastia R for the Texas Alzheimer's Research Consortium Serum brain-derived neurotrophic factor levels are specifically associated with memory performance among Alzheimer's disease cases. Dement Geriatr Cogn Disord 31, 31-36.
12. Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E, Bartels M, Buchkremer G, Schott K (2006) Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm 113, 1217-1224. (Pubitemid 44291016)
13. O'Bryant SE, Waring SC, Hobson V, Hall JR, Moore CB, Bottiglieri T, Massman P (2010) Diaz-Arrastia R Decreased C-reactive protein levels in Alzheimer disease. J Geriatr Psychiatry Neurol 23, 49-53.
14. Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C (2002) Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 23, 485-508. (Pubitemid 34495461)
15. Hampel H, ShenY,Walsh DM, Aisen P, ShawLM, Zetterberg H, Trojanowski JQ, Blennow K (2010) Biological markers of amyloid β-related mechanisms in Alzheimer's disease. Exp Neurol 223, 334-346.
16. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362. (Pubitemid 350073592)
17. Buerger K, Ernst A, Ewers M, Uspenskaya O, Omerovic M, Morgenthaler NG, Knauer K, Bergmann A, Hampel H (2009) Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio. Biol Psychiatry 65, 979-984.
18. Laske C, Leyhe T, Stransky E, Hoffmann N, Fallgatter AJ, Dietzsch J (2011) Identification of a blood-based biomarker panel for classification of Alzheimer's disease. Int J Neuropsychopharmacol 14, 1147-1155.
19. Nagele E, Han M, DeMarshall C, Belinka B, Nagele R (2011) Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One 6, e23112.
20. Reddy MM,Wilson R,Wilson J, Connell S, Gocke A, Hynan L, German D, Kodadek T (2011) Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell 144, 132-142.
21. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S (2010) Diaz-Arrastia R for the Texas Alzheimer's Research Consortium A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67, 1077-1081.
22. O'Bryant SE, Xiao G, Barber R, Reisch J, Hall J, Cullum CM, Doody R, Fairchild T, Adams P, Wilhelmsen K (2011) Diaz-Arrastia R for the Texas Alzheimer's Research and Care Consortium A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord 32, 55-62.
23. O'Bryant SE, Xiao G, Barber R, Huebinger R,Wilhelmsen K, Edwards M, Graff-Radford N, Doody R Diaz-Arrastia R for the Texas Alzheimer's Research & Care Constortium and the Alzheimer's Disease Neuroimaging Initiative (2011)A blood based screening tool for Alzheimer's disease that spans serum and plasma: Findings from TARC and ADNI. PLoS One 6, e28092.
24. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG (2007) Association of lowplasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64, 354-362. (Pubitemid 46425689)
25. Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, Younkin LH, Kuller L, Ayonayon HN, Ding J, Harris TB (2011) Association of plasma β-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305, 261-266.
26. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J (2006) Risk score for the prediction of dementia risk in 20 years among middle aged people: A longitudinal, population-based study. Lancet 5, 735-740.
27. van Oijen M,Witteman JC, Hofman A,Koudstaal PJ, Breteler MM (2005) Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 36, 2637-2641.
28. Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, Benjamin EJ, Au R, Kiel DP, Wolf PA, Seshadri S (2007) Inflammatory markers and the risk of Alzheimer disease: The Framingham study. Neurology 68, 1902-1908. (Pubitemid 46848622)
29. van Exel E, Eikelenboom P, Comijs H, Frolich M, Smit JH, Stek ML, Scheltens P, Eefsting JE, Westendorp RG (2009) Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Arch Gen Psychiatry 66, 1263-1270.
30. Nilsson K, Gustafson L, Hultberg B (2011) C-reactive protein level is decreased in patients with Alzheimer's disease and related to cognitive function and survival time. Clin Biochem 44, 1205-1208.
31. Laske C, Sopova K, Gkotsis C, Eschweiler GW, Straten G, Gawaz M, Leyhe T, Stellos K (2010) Amyloid-Beta peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients. J Alzheimers Dis 21, 1263-1269.
32. Laske C, Stellos K, Hoffmann N, Stransky E, Straten G, Eschweiler GW, Leyhe T (2011) Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients. Int J Neuropsychopharmacol 14, 399-404.
33. Stellos K, Panagiota V, Kogel A, Leyhe T, Gawaz M, Laske C (2010) Predictive value of platelet activation for the rate of cognitive decline in patients with dementia. J Cereb Blood Flow Metab 30, 1817-1820.
34. O'Bryant S (2012) Using blood markers for Alzheimer's disease in clinical practice? Neurology 79, 846-847.
35. Mayeux R, Reitz C, Brickman AM, Hann MN, Manly JJ, Glymour MM, Weiss CC, Yaffe K, Middleton L, Hendrie HC, Warren LH, Kayden KM, Welsh-Bohmer KA, Breitner JC, Morris JC (2011) Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment - Part 1. Alzheimers Dement 7, 15-34.
36. Jun G, Naj AC, Beecham GW,Wang LS, Buros J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, FallinMD,Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P, Cantewell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL, Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D, Cupples LA, Hakonarson H, Kukull W, Foroud TM, Haines J, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD (2010) Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with ApoEε4 genotypes. Arch Neurol 67, 1473-1484.
37. Bertoli Avella AM, Marcheco Teruel B, Llibre Rodriguez JJ, Gomex Viera N, Borrajero Martinez I, Severijnen EA, Joosse M, van Duijn CM, Heredero Baute L, Heutink P (2002) A novel presenilin 1 mutation (L174 M) in a large Cuban family with early onset Alzheimer disease. Neurogenetics 4, 97-104. (Pubitemid 36019505)
38. Ramos MI, Allen LH, Mungas DM, Jaqust WJ, Haan MN, Green R, MillerJW(2005) Lowfolate status is associated with impaired cognitive function and dementia in the Sacramento Area Latino Study on Aging. Am J Clin Nutr 82, 1346-1352. (Pubitemid 43779735)
39. Haan MN, Miller JW, Aiello AE, Whitmer RA, Jaqust WJ, Mungas DM, Allen LH, Green R (2007) Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: Results from the Sacramento Area Latino Study on Aging. Am J Clin Nutr 85, 511-517. (Pubitemid 46220956)
40. Miller JW, Green R, Ramos MI, Allen LH, Mungas DM, Jaqust WJ, Hann MN (2003) Homocysteine and cognitive function in the Sacramento Area Latino Study on Aging. Am J Clin Nutr 78, 441-447. (Pubitemid 39663511)
41. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM,Morris JC, Trojanowski JQ, SoaresHfor the Alzheimer's Disease Nueroimaing Initiative (2012) Plasma multi-analyte profiling in mild cognitive impairment and Alzheimer's disease. Neurology 79, 897-905.
42. O'Bryant SE, Johnson L, Edwards M, Soares H, Devous MD, Ross S, Rohlfing G, Hall J for the Texas Alzheimer's Research & Care Consortium (2013) The link between C-reactive protein and Alzheimer's disease among Mexican Americans. J Alzheimers Dis 34(3), 701-706.
43. Veeranna V, Zalawadiya SK, Niraj A, Kumar A, Ference B, Afonso L (2012) Association of novel biomarkers with future cardiovascular events is influenced by ethnicity: Results from a multi-ethnic cohort. Int J Cardiol, doi: 10.1016/j.ijcard.2011.11.034 [Epub ahead of print].
44. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
45. Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412-2414. (Pubitemid 23346995)
46. O'Bryant SE, Waring SC, Cullum CM, hall J, Lacritz L, Massman PJ, Lupo PJ, Reisch JS (2008) Doody R for the Texas Alzheimer's Research Constorium Staging dementia using clinical dementia rating scale sum of boxes scores: A Texas Alzheimer's research consortium study. Arch Neurol 65, 1091-1095.
47. O'Bryant SE, Lacritz LH, Hall J,Waring SC, ChanW, Khodr ZG, Massman PJ, Jobson V, Cullum CM (2010) Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the National Alzheimer's Coordinating Center database. Arch Neurol 67, 746-749.
48. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
49. Ivnik R, Malec JF, Smith GE, Tangalos EG, Petersen RC, Kokmen E, Kurkland LT (1992) Mayo's Older Americans Normative Studies: WAIS-R norms for age 56 to 97. Clin Neuropsychol 6, 1-30.
50. Koch W, Ehrenhaft A, Griesser K, Pfeufer A, Muller J, Schomig A, Kastrati A (2002) TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. Clin Chem Lab Med 40, 1123-1131. (Pubitemid 36032659)
51. R Development Core Team (2009) R: A language and environment for statistical computing, http://www. R-project.org.
52. Breiman L (2001) Random forests. Machine Learning 45, 5-32. (Pubitemid 32933532)
53. Crean S,Ward A, Mercaldi CJ, Collins JM, Cook MN, Baker NL, Arrighi HM (2011) Apolipoprotein E e4 prevalence in Alzheimer's disease patients varies across global populations: A systematic literature review and meta-analysis. Dement Geriatr Cogn Disord 31, 20-30.
54. Sundquist J,Winkleby MA, Pudaric S (2001) Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: An analysis of NHANES III, 1988-1994. Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 49, 109-116. (Pubitemid 32207218)
55. Black SA, Ray LA, Markides KS (1999) The prevalence and health burden of self-reported diabetes in older Mexican Americans: Findings from the Hispanic established populations for epidemiologic studies of the elderly. Am J Public Health 89, 546-552. (Pubitemid 29279667)
56. Otiniano ME, Du XL, Maldonado MR, Ray L, Markides K (2005) Effect of metabolic syndrome on heart attack and mortality in Mexican-American elderly persons: Findings of 7-year follow-up from the Hispanic established population for the epidemiological study of the elderly. J Gerontol A Biol Sci Med Sci 60, 466-470. (Pubitemid 40712863)
57. Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356-359. (Pubitemid 34251969)
58. Bu L, Salto LM, De Leon KJ, De Leon M (2011) Polymorphisms in fatty acid binding protein 5 show association with type 2 diabetes. Diabetes Res Clin Pract 92, 82-91.
59. Damcott CM, Feingold E, Moffett SP, Barmada MM, Marshall JA, Hamman RF, Ferrell RE (2003) Variation in the FABP2 promoter alters transcriptional activity and is associated with body composition and plasma lipid levels. Hum Genet 112, 610-616. (Pubitemid 36869056)
60. Vaidya D, Szklo M, Cushman M, Holvoet P, Polak J, Bahrami H, Jenny NS, Ouyang P (2011) Association of endothelial and oxidative stress with metabolic syndrome and subclinical atherosclerosis: Multi-ethnic study of atherosclerosis. Eur J Clin Nutr 65, 818-825.
61. Cho YM, Merchant CE, Kieffer TJ (2012) Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Ther 135, 247-278.
62. Roth JD, Erickson MR, Chen S, Parkes DG (2012) GLP-1R and amylin agonism in metabolic disease: Complementary mechanisms and future opportunities. Br J Pharmacol 166, 121-136.
63. Banerjee A, Onyuksel H (2012) Human pancreatic polypeptide in a phospholipid-based micellar formulation. Pharm Res 29, 1698-1711.
64. Hoffman KE, Derdak J, Bernstein D, Reynolds JC, Avila NA, Gerber L, Steinberg SM, Chrousos G, Mackall CL, Mansky PJ (2008) Metabolic syndrome traits in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer 50, 341-346.
65. Touskova V, Trachta P, Kavalkova P, Drapalova J, Haluzikova D, Mraz M, Lacinova Z, Marek J, Haluzik M (2012) Serum concentrations and tissue expression of components of insulin-like growth factor-axis in females with type 2 diabetes mellitus and obesity: The influence of very-low-calorie diet. Mol Cell Endocrinol 361, 172-178.
66. Pimentel GD, Micheletti TO, Pace F, Rosa JC, Santos RV, Lira FS (2012) Gut-central nervous system axis is a target for nutritional therapies. Nutr J 11, 22.
67. Azizi F, Moazezi Z, Hedayati M, Shirkhani Z (2012) Glucose intolerance in subclinical hyperthyroid patients. Iran J Endocrinol Metab 14, 4.
68. James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH, Cutler P, Bock K, Boris M, Bradstreet JJ, Baker SM, GaylorDW(2006) Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 141, 947-956. (Pubitemid 44905454)
69. Braff DL, Light GA (2005) The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues Clin Neurosci 7, 125-135. (Pubitemid 40961532)
70. Doecke J, Laws SM, Faux NG,WilsonW, Burnham SC, Lam CP, Mondal A, Bedo J, Busy AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay L, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Aimes D, Masters CL, Martins RN (2012) Blood-based protein biomarkers for the diagnosis of Alzheimer's disease. Arch Neurol 69, 1-8.